Scientific Advisory Board (SAB)

A scientific advisory board (SAB) reflecting the key expertise and skill sets that STRONG requires has been constituted and includes academic and statistical experts, as well as a member of the advocacy group for people with glaucoma and ophthalmological diseases and Orphanet, representative of people with rare diseases. The SAB will serve as independent advisors to the consortium and, in addition to Professor Pfeiffer, will comprise of the following representatives:

Roger Hitchings, Past President European Glaucoma Society, Glaucoma specialist at Moorfields Eye Hospital, Great Britain, and Scientific Director emeritus

Carlo Traverso, President of the European Glaucoma Society, Director of Clinica Oculista, University of Genova, Italy

Professor Gabriel Coscas, MD, PhD ex Chairman of the Ophthalmology Department at Paris University-XII, and ex-President of the French Retinal Society

Professor Peter A. Campochiaro, MD, PhD Wilmer Eye Institute, Johns Hopkins University School of Medicine, for extensive expertise in ophthalmic drug development

Prof. Dr. Gu╠łnter K. Krieglstein, Cologne, for expertise in glaucoma and clinical trials

Professor Giuseppe Ambrosio, PhD, MD, Director of Cardiology University of Perugia School of Medicine, for expertise on microcirculation

Professor Rodney Taylor, MSc, PhD, Professor in Health Services Research, Peninsula Medical School, Universities of Exeter & Plymouth, for expertise with statistical analysis

Prof. Dr. Hansj├╝rgen Agostini, Freiburg, for expertise in retinal diseases and clinical trials

They will act as the oversight body for this trial on behalf of the Sponsor/Funder. The role of the SAB is to provide oversight for the trial according to MRC and GCP guidelines. They will deliver opinion and advice in work package execution.